Abstract: There is disclosed a method of preparing a plasma protein-containing medicament from citrated plasma or from a citrate-containing plasma fraction, the medicament being substantially free from undesired metals, which method comprises the following steps exchanging the citrate and optionally citrate-bound metals in a plasma-protein-containing solution for a water-soluble mono- or dicarboxylate or for an organic mono- or dicarboxylic acid under non-precipitating conditions, recovering the plasma protein or the plasma proteins, and finishing the medicament.

Abstract: There is disclosed a method of preparing a plasma-protein-containing medicament from citrated plasma or from a citrate-containing plasma fraction, the medicament being substantially free from undesired metals, which method comprises the following steps: exchanging the citrate and optionally citrate-bound metals in a plasma-protein-containing solution for a water-soluble mono- or dicarboxylate or for an organic mono- or dicarboxylic acid under non-precipitating conditions, recovering the plasma protein or the plasma proteins, and finishing the medicament.

Abstract: There is disclosed a method of preparing a plasma-protein-containing medicament from citrated plasma or from a citrate-containing plasma fraction, the medicament being substantially free from undesired metals, which method comprises the following steps: exchanging the citrate and optionally citrate-bound metals in a plasma-protein-containing solution for a water-soluble mono- or dicarboxylate or for an organic mono- or dicarboxylic acid under non-precipitating conditions, recovering the plasma protein or the plasma proteins, and finishing the medicament.

Abstract: The invention relates to a method for the production of factor VIII:C/von Willebrand factor complex from plasma or a plasma fraction by chromatography in a cation exchanger, wherein the factor VIII:C/von Willebrand factor complex is obtained with at least 300 times the purity of the plasma and the yield of factor VIII:C and the von Willebrand factor is at least 50% in relation to cryoprecipitates or analogous plasma fractions.

Abstract: The invention relates to the use of human &agr;1-acid glycoprotein (AGP) for producing a pharmaceutical preparation for treating non-inflammatory disturbances of circulation or microcirculation, respectively.

Abstract: A method of purifying antithrombin III (AT III) from a starting material containing an AT III/heparin complex or an AT III/heparinoid complex is disclosed. First, the method comprises adsorbing the AT III/heparin complex or the AT III/heparinoid complex on an anion exchanger material. Second, the method involves separating the AT III from the adsorbed AT III/heparin complex or an AT III/heparinoid complex by elution with a buffer having a pH ranging from 8.5 to 10.5 and a conductivity between 10 and 60 mS.

Abstract: There is disclosed a method of preparing a plasma-protein-containing medicament from citrated plasma or from a citrate-containing plasma fraction, the medicament being substantially free from undesired metals, which method comprises the following steps:

Abstract: There is disclosed a highly purified complex comprising the components factor VIII and vWF having a specific activity of at least 70, preferably 100 to 300 U factor VIII:C/mg, a stable pharmaceutical preparation containing this complex as well as a method of producing the same.

Abstract: A method is described for production of a C1-INH esterase inhibitor (C1-INH)-containing composition, which includes the following steps:

Abstract: A blood product, exclusive of albumin, inactivated relative to infectious agents, the blood product conforming to a total virus reduction factor of at least 40, having a biological acitity of at least 50%, based on its activity prior to effecting inactivation of the infectious agents, the blood product being producible from conventional blood products and being virus-safe.

Abstract: Inflammation can be treated or prevented altogether by administering a preparation comprising IgA. These preparations also can effect immunomodulation. Preferably, the preparation includes multimeric IgA and is essentially free of IgG in its various forms. Other compounds, such as antibiotics, antiphlogistic agents and antacids, also may be administered. Immunoglobulin A may also be used in vaccines to prevent inflammation. Additionally, an improved assay for evaluating anti-inflammatory activity is provided.

Abstract: A thrombin of human or animal origin is free of infectious agents and is produced by activation of prothrombin subjected to a heat treatment for the inactivation of infectious agents.

Abstract: This invention is directed to a method of evaluating viral reduction capability of a viral inactivation step in a viral inactivation procedure. The method requires spiking a biological product with a virus more than once during the viral inactivation step so that a virus reduction factor can be calculated.

Abstract: A stable, highly concentrated intravenously tolerable immunoglobulin preparation is described having an immunoglobulin content from 13.5 to 17.5% (w/v), an osmolarity from 250 to 600 mOs/l and a viscosity of no more than 9 cP. The immunoglobulin preparation possesses an exceptional imperishability and also is used as a highly concentrated preparation without problems due to its low viscosity.

Abstract: A thrombolytic, parenterally administrable drug containing activated protein C is provided for. The drug is free of serum amyloid P, thrombin activity, infectious agents and antibodies against protein C and activated protein C.

Abstract: A process for preparing lys-plasminogen from blood plasma or blood plasma products having a specific activity of at least 17.5 caseinolytic units/mg protein and at lease 50 .mu.moles/g protein nitrogen as well as a an electrophoretic purity of at least 90% is presented. Cohn fraction III is obtained by phosphate precipitation from blood plasma or blood plasma products. A crude plasminogen fraction is then obtained by precipitating most non-plasminogen proteins with ethanol. The crude plasminogen is absorbed on immobilized lysine affinity column. Elution followed by precipitation obtains a purified plasminogen. The purified plasminogen is converted to lys-plasminogen with plasmin having an activity from 0.01 to 0.1 .mu.moles/ml min relative to chromogenic substrate H-D-Val-L-Leu-L-Lys-p-nitroanilide by dialyzing at a temperature of about 1.degree. to 20.degree. C. for a time period of about 6 to 60 hours. The conversion is interrupted by adding aprotinin.

Abstract: A method of dissolving venous thrombi using a thrombolytic, parenterally administrable drug containing activated protein C is described. The drug can be free of serum amyloid P, thrombin activity, infectious agents and antibodies against protein C and activated protein C.

Abstract: Factor IX is selectively adsorbed by means of hydrophobic chromatography from an aqueous mixture containing at least one plasma zymogen or a vitamin-K dependent protein in addition to factor IX. By this method, the efficient enrichment of factor IX for the production of pharmaceutical preparations has become possible.

Abstract: The invention relates to a method of producing virus-safe highly purified factor VIII. The method includes a combination of the following measures:a) chromatographic purification of a factor VIII-containing fraction,b) tenside treatment of factor VIII in an aqueous solution at a tenside/protein ratio of from 1:1 to 1000:1, andc) heat treatment of the factor VIII preparation in the solid state.

Abstract: There is disclosed a method of activating prothrombin by means of trypsin, wherein the prothrombin is recovered from a blood or plasma fraction, treated with trypsin immobilized on a water-insoluble carrier, and separated from the immobilized trypsin after activation.